Literature DB >> 20805179

Validation of a parent-proxy quality of life questionnaire for paediatric chronic cough (PC-QOL).

Peter A Newcombe1, Jeanie K Sheffield, Elizabeth F Juniper, Helen L Petsky, Carol Willis, Anne B Chang.   

Abstract

BACKGROUND: Quality of life (QOL) measures are an important patient-relevant outcome measure for clinical studies. Currently there is no fully validated cough-specific QOL measure for paediatrics. The objective of this study was to validate a cough-specific QOL questionnaire for paediatric use.
METHOD: 43 children (28 males, 15 females; median age 29 months, IQR 20-41 months) newly referred for chronic cough participated. One parent of each child completed the 27-item Parent Cough-Specific QOL questionnaire (PC-QOL), and the generic child (Pediatric QOL Inventory 4.0 (PedsQL)) and parent QOL questionnaires (SF-12) and two cough-related measures (visual analogue score and verbal category descriptive score) on two occasions separated by 2-3 weeks. Cough counts were also objectively measured on both occasions.
RESULTS: Internal consistency for both the domains and total PC-QOL at both test times was excellent (Cronbach alpha range 0.70-0.97). Evidence for repeatability and criterion validity was established, with significant correlations over time and significant relationships with the cough measures. The PC-QOL was sensitive to change across the test times and these changes were significantly related to changes in cough measures (PC-QOL with: verbal category descriptive score, r(s)=-0.37, p=0.016; visual analogue score, r(s)=-0.47, p=0.003). Significant correlations of the difference scores for the social domain of the PC-QOL and the domain and total scores of the PedsQL were also noted (r(s)=0.46, p=0.034).
CONCLUSION: The PC-QOL is a reliable and valid outcome measure that assesses QOL related to childhood cough at a given time point and measures changes in cough-specific QOL over time.

Entities:  

Mesh:

Year:  2010        PMID: 20805179     DOI: 10.1136/thx.2009.133868

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

Review 1.  An update on measurement and monitoring of cough: what are the important study endpoints?

Authors:  Arietta Spinou; Surinder S Birring
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Can a management pathway for chronic cough in children improve clinical outcomes: protocol for a multicentre evaluation.

Authors:  A B Chang; C F Robertson; P P van Asperen; N J Glasgow; I B Masters; C M Mellis; L I Landau; L Teoh; P S Morris
Journal:  Trials       Date:  2010-11-06       Impact factor: 2.279

3.  Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.

Authors:  Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

4.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

Review 5.  Review: Quality of Life in Children with Non-cystic Fibrosis Bronchiectasis.

Authors:  Anna Marie Nathan; Jessie Anne de Bruyne; Kah Peng Eg; Surendran Thavagnanam
Journal:  Front Pediatr       Date:  2017-04-24       Impact factor: 3.418

Review 6.  Analysis of the Literature on Chronic Cough in Children.

Authors:  Marcello Bergamini; Ahmad Kantar; Renato Cutrera; Italian Pediatric Cough Interest Group
Journal:  Open Respir Med J       Date:  2017-04-27

7.  Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study.

Authors:  Yolanda G Lovie-Toon; Keith Grimwood; Catherine A Byrnes; Vikas Goyal; Greta Busch; I Brent Masters; Julie M Marchant; Helen Buntain; Kerry-Ann F O'Grady; Anne B Chang
Journal:  BMC Health Serv Res       Date:  2019-08-13       Impact factor: 2.655

8.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

9.  Bronchiectasis - Exercise as Therapy (BREATH): rationale and study protocol for a multi-center randomized controlled trial.

Authors:  Taryn Jones; Kerry-Ann F O'Grady; Vikas Goyal; Ian B Masters; Gabrielle McCallum; Christopher Drovandi; Thomas Lung; Emmah Baque; Denise S K Brookes; Caroline O Terranova; Anne B Chang; Stewart G Trost
Journal:  Trials       Date:  2022-04-11       Impact factor: 2.279

10.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.